JP2024500335A5 - - Google Patents
Info
- Publication number
- JP2024500335A5 JP2024500335A5 JP2023534635A JP2023534635A JP2024500335A5 JP 2024500335 A5 JP2024500335 A5 JP 2024500335A5 JP 2023534635 A JP2023534635 A JP 2023534635A JP 2023534635 A JP2023534635 A JP 2023534635A JP 2024500335 A5 JP2024500335 A5 JP 2024500335A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- complex according
- seq
- isolated polypeptide
- polypeptide complex
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063122820P | 2020-12-08 | 2020-12-08 | |
| US63/122,820 | 2020-12-08 | ||
| PCT/US2021/062233 WO2022125562A1 (en) | 2020-12-08 | 2021-12-07 | Peptide compositions and methods for anti-cd3 binding domains |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024500335A JP2024500335A (ja) | 2024-01-09 |
| JP2024500335A5 true JP2024500335A5 (https=) | 2024-12-12 |
Family
ID=81973732
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023534635A Pending JP2024500335A (ja) | 2020-12-08 | 2021-12-07 | 抗ｃｄ３結合ドメインのためのペプチド組成物および方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240043536A1 (https=) |
| EP (1) | EP4259177A4 (https=) |
| JP (1) | JP2024500335A (https=) |
| KR (1) | KR20230137301A (https=) |
| CN (1) | CN116981682A (https=) |
| AU (1) | AU2021396507A1 (https=) |
| CA (1) | CA3201401A1 (https=) |
| MX (1) | MX2023006733A (https=) |
| WO (1) | WO2022125562A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023013382A (es) | 2020-04-04 | 2024-01-30 | Janux Therapeutics Inc | Composiciones y metodos relacionados con anticuerpos activados contra tumores dirigidos a egfr y antigenos de celulas efectoras. |
| AU2021396172A1 (en) | 2020-12-09 | 2023-07-06 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
| EP4615514A2 (en) * | 2022-11-10 | 2025-09-17 | Janux Therapeutics, Inc. | Antibodies targeting egfr and cd3 and uses thereof |
| WO2026002279A1 (en) * | 2024-06-28 | 2026-01-02 | Vibrant Pharma Limited | Mask peptide, cleavable substrate, multispecific antibodies and uses thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2955947A1 (en) * | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| EP3322715B1 (en) * | 2015-07-14 | 2023-10-18 | BioNTech SE | Peptide mimotopes of the cd3 t-cell co-receptor epsilon chain and uses thereof |
| MX2023013382A (es) * | 2020-04-04 | 2024-01-30 | Janux Therapeutics Inc | Composiciones y metodos relacionados con anticuerpos activados contra tumores dirigidos a egfr y antigenos de celulas efectoras. |
| WO2022094299A2 (en) * | 2020-10-30 | 2022-05-05 | Janux Therapeutics, Inc. | Multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof |
| EP4259202A4 (en) * | 2020-12-09 | 2025-01-15 | Janux Therapeutics, Inc. | COMPOSITIONS AND METHODS RELATED TO TUMOR-ACTIVATED ANTIBODIES AGAINST TROP2 AND EFFECTOR CELL ANTIGENS |
| AU2021396172A1 (en) * | 2020-12-09 | 2023-07-06 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
-
2021
- 2021-12-07 US US18/256,278 patent/US20240043536A1/en active Pending
- 2021-12-07 JP JP2023534635A patent/JP2024500335A/ja active Pending
- 2021-12-07 AU AU2021396507A patent/AU2021396507A1/en active Pending
- 2021-12-07 EP EP21904260.3A patent/EP4259177A4/en active Pending
- 2021-12-07 CA CA3201401A patent/CA3201401A1/en active Pending
- 2021-12-07 KR KR1020237023034A patent/KR20230137301A/ko active Pending
- 2021-12-07 WO PCT/US2021/062233 patent/WO2022125562A1/en not_active Ceased
- 2021-12-07 MX MX2023006733A patent/MX2023006733A/es unknown
- 2021-12-07 CN CN202180092543.9A patent/CN116981682A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024500335A5 (https=) | ||
| AU2022218544A1 (en) | Hetero-dimeric multi-specific antibody format | |
| JP2021106617A5 (https=) | ||
| JP2020114210A5 (https=) | ||
| RU2317999C2 (ru) | SCFV ПРОТИВ EGFRvIII С УЛУЧШЕННОЙ ЦИТОТОКСИЧНОСТЬЮ И ВЫХОДОМ, ИММУНОТОКСИНЫ НА ИХ ОСНОВЕ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| WO2021136483A1 (en) | Anti-trop2 antibodies, antibody-drug conjugates, and application of the same | |
| JP2021522162A5 (https=) | ||
| JP2021159081A5 (https=) | ||
| JP2021530251A5 (https=) | ||
| JP2005507635A5 (https=) | ||
| JP2023527609A5 (https=) | ||
| JP2020533311A5 (ja) | ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質 | |
| IL295295A (en) | Antibodies targeting fc receptor-like 5 and methods of use | |
| HRP20161216T1 (hr) | Farmaceutski pripravci s otpornošću na topljivi cea | |
| JP2024527288A5 (https=) | ||
| JP2022527151A5 (https=) | ||
| JP2020505919A5 (https=) | ||
| JP2011526249A5 (https=) | ||
| JP2022543669A5 (https=) | ||
| JP2025160226A5 (https=) | ||
| JP2024119984A5 (https=) | ||
| JP2023506834A5 (https=) | ||
| JP2023552462A5 (https=) | ||
| CN1381461A (zh) | 抗人肝癌单克隆抗体HAb18轻、重链可变区基因及其应用 | |
| JP2021529524A5 (https=) |